Evidence map›Paper›PMID 38612496›Full record

ArticleInternational journal of molecular sciences2024

Impact of

Paula Soria-Chacartegui, Marcos Navares-Gómez, Francisca Molina-Jiménez, Emilio J Laserna-Mendieta, Laura Arias-González, Pedro Majano, Sergio Casabona, Alfredo J Lucendo, Francisco Abad-Santos, Cecilio Santander and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Paula Soria-ChacarteguiClinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), 28006 Madrid, Spain.ORCID 0000-0002-1951-2626
Marcos Navares-GómezClinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), 28006 Madrid, Spain.
Francisca Molina-JiménezInstituto de Investigación Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain.
Emilio J Laserna-MendietaInstituto de Investigación Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain.ORCID 0000-0002-9039-7667
Laura Arias-GonzálezInstituto de Investigación Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain.ORCID 0000-0003-2132-9350
Pedro MajanoInstituto de Investigación Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain.
Sergio CasabonaInstituto de Investigación Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain.ORCID 0000-0002-6131-8341
Alfredo J LucendoInstituto de Investigación Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain.ORCID 0000-0003-1183-1072
Francisco Abad-SantosClinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), 28006 Madrid, Spain.ORCID 0000-0002-6519-8885
Cecilio SantanderInstituto de Investigación Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain.ORCID 0000-0001-5492-2535
Pablo ZubiaurClinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), 28006 Madrid, Spain.ORCID 0000-0002-6150-4320
Instituto de Salud Carlos III · ESHospital Universitario de La Princesa · ESUniversidad Complutense de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proton pump inhibitors (PPIs) are the first-line drug for eosinophilic esophagitis (EoE), although it is estimated that there is a lack of histological remission in 50% of patients. This research aimed to identify pharmacogenetic biomarkers predictive of PPI effectiveness and to study their association with disease features. Peak eosinophil count (PEC) and the endoscopic reference score (EREFS) were determined before and after an eight-week PPI course in 28 EoE patients. The impact of the signal transducer and activator of transcription 6 (

Indexed as

EnteritisEosinophiliaEosinophilic EsophagitisGastritisComorbidityHumansProton Pump InhibitorsSTAT6 Transcription FactorProton Pump InhibitorsSTAT6 protein, humanSTAT6 Transcription FactorCYP2C19eosinophilic esophagitispharmacogeneticsSTAT6

Identifiers

PMID38612496
PMCPMC11011338
OpenAlexW4393189443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.